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Abstract
Purpose: We sought to compare the economic impact of treatment-related adverse events (AEs) in patients with
metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or second-line
(FL or SL) therapy in the US.
Methods: We used healthcare claims data from the Truven Health Analytics MarketScan® Commercial Databases to
conduct a retrospective cohort study comparing the economic impact of AEs amongst taxane- and capecitabine-
treated mBC patients in the US. We selected women diagnosed with mBC between 2008–2010 who received a taxane
or capecitabine as first- or second-line (FL or SL) chemotherapy. Costs related to hospitalization, outpatient services,
emergency department visits, chemotherapy and other medications were tabulated and combined to determine total
healthcare costs. The incremental monthly costs associated with the presence of AEs compared to no AEs were
estimated using generalized linear models, controlling for age and Charlson Comorbidity Index.
Results: We identified 15,443 mBC patients meeting inclusion criteria. Adjusted total monthly costs were significantly
higher in those who experienced AEs than in those without AEs in both lines of treatment (FL incremental cost:
taxanes $1,142, capecitabine $1,817; SL incremental cost: taxanes $1,448, capecitabine $4,437). Total costs increased
with the number of AEs and were primarily driven by increased hospitalization amongst those with AEs.
Conclusions: Adverse events in taxane- or capecitabine-treated mBC patients are associated with significant increases
in costs. Selecting treatment options associated with fewer AEs may reduce costs and improve outcomes in these
patients.
Keywords: Breast neoplasms; Adverse effects; Antineoplastic agents; Costs and cost analysis
Introduction
It is estimated that over 155,000 women are currently liv-
ing with metastatic breast cancer (mBC) in the United
States (US) (Metastatic Breast Cancer Network 2010).
Treatment for mBC is generally considered palliative in
intent, and the primary goals are to prolong survival while
improving symptoms and preserving quality of life (Beslija
et al. 2009). Selecting amongst available treatment options
is complex and depends upon numerous factors, such as
patient preferences and characteristics, comorbidities,
symptoms, location/extent of metastases, history of prior
treatments, and tumor markers (Beslija et al. 2009; National
Comprehensive Cancer Network 2013). In addition, poten-
tial treatment-related side effects should be considered
(Beslija et al. 2009). Chemotherapy-related adverse events
(AEs) are common, and toxicity profiles vary across agents.
Adverse events impact patient quality of life and can result
in treatment interruptions or dose reductions, which in
turn may decrease treatment efficacy (Kayl and Meyers
2006; Hwang et al. 2013). Furthermore, chemotherapy-
related AEs can result in substantial increases in costs
(Guerin et al. 2011; Hurvitz et al. 2012; Chu et al. 2009;
Stokes et al. 2009; Craver et al. 2011).
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The National Comprehensive Cancer Network Clinical
Practice Guidelines (NCCN Guidelines) recommend vari-
ous chemotherapeutic agents, used either as monotherapy
or in combination, to prolong survival in patients with
mBC (National Comprehensive Cancer Network 2013).
Taxanes, such as paclitaxel and docetaxel, are commonly
used. The NCCN guidelines list paclitaxel as a preferred
single agent and docetaxel as an alternative single agent in
the treatment of mBC (National Comprehensive Cancer
Network 2013). Both of these agents are administered
intravenously and may be used alone or as a part of a com-
bination regimen. Capecitabine, an orally administered anti-
metabolite, is also listed by the NCCN guidelines as a
preferred single agent in the treatment of mBC (National
Comprehensive Cancer Network 2013). However, the cost
of AEs related to capecitabine and taxanes in mBC patients
is not well understood. An earlier analysis investigating this
issue used the PharMetrics® Integrated Database to analyze
healthcare costs amongst patients with mBC receiving a
taxane or capecitabine and found that chemotherapy-
related AEs were associated with a substantial economic
burden, driven by increased inpatient, outpatient, and phar-
macy costs (Hurvitz et al. 2012).
The current study investigates a similar question, using
a different healthcare claims database. The results of this
study will serve as a validation of previous work, using a
different methodology. Our objective was to compare the
economic impact of treatment-related AEs in patients
with mBC using taxane- or capecitabine-based treatment
regimens as either first- or second-line (FL or SL) therapy
in the US.
Methods
Design and data source
We conducted a retrospective cohort study among pa-
tients with mBC treated with a taxane or capecitabine in
the first or second line setting. Healthcare claims data
from the Truven Health Analytics MarketScan® Commer-
cial Databases were used to identify line of treatment and
to estimate AE frequency and costs. The MarketScan data-
base includes comprehensive claim-level data on inpatient,
outpatient, and prescription drug claims for over 90 million
employed individuals and their dependents in the US.
Claims data are also matched to administrative records,
which provide demographic information and monthly in-
surance coverage status, allowing for longitudinal tracking
of individuals.
We selected women with claims indicating a diagnosis
of secondary malignant neoplasm (International Classifi-
cation of Diseases version 9 [ICD-9] 196.X-198.X) occur-
ring between 2008–2010 (Figure 1). The first metastatic
cancer diagnosis was set as the “disease index date.” In
order to restrict the sample to those with metastatic breast
cancer, we required that patients have: (1) at least one
claim with a breast cancer diagnosis (ICD-9 174.X, 233.0,
85.20–85.23, 85.41–85.48) within the 365 days prior to dis-
ease index, and (2) at least one additional claim with a
breast cancer diagnosis, as defined above, within 365 days
prior to or 90 days after disease index. In addition, patients
were excluded if they had any claims for a cancer other
than breast cancer (defined as ICD-9-CM 140.x-165.x, 170.
x-173.x, 7 175.x-176.x, 179.x-195.x, and 199.x-209.x) prior
to disease index. Additional eligibility criteria included: (1)
continuous insurance coverage for one year prior to and
one year after disease index, (2) at least one claim for a
chemotherapy drug for breast cancer after disease index, (3)
continuous insurance coverage for at least one year prior to
and 30 days after the first chemotherapy treatment, and (4)
at least one treatment episode with a taxane (paclitaxel or
docetaxel) or capecitabine as FL or SL therapy.
The date of treatment initiation with a chemotherapeutic
agent, following disease index, was designated the “study
index date”. Patients were followed longitudinally, using
pharmacy dispensing and medical claims data to determine
each patient’s course of treatment. The follow-up period
began at study index and ran until the end of continuous
health plan enrollment or the end of data availability, which-
ever came first. This period included one or more treatment
episode(s) with a taxane or capecitabine. A treatment epi-
sode was defined as the period from treatment initiation
until a gap in treatment of over 45 consecutive days or a
change in regimen (switching medications, adding a new
medication, or discontinuing a medication). Only treatment
episodes lasting at least 30 days were included in the ana-
lysis. For each treatment episode, eligible patients were cate-
gorized into one of four treatment cohorts: (1) first-line
taxane, (2) first-line capecitabine, (3) second-line taxane, or
(4) second-line capecitabine. Episodes were excluded in
which patients received both a taxane and capecitabine, but
patients could use each agent during separate treatment epi-
sodes. Patients were assigned to treatment cohorts using a
published algorithm, which incorporates both pharmacy
and medical claims data (using Health Care Procedure J-
codes and National Drug Codes) (Hurvitz et al. 2012).
Chemotherapy-related AEs were identified in the in-
patient and outpatient service-level data, based on ICD-9
codes (Table 1). The list of investigated AEs was developed
based on a combination of published data, package inserts
and clinical opinion (Hurvitz et al. 2012). Adverse events
were attributed to the treatment received during the epi-
sode in which the diagnosis of the AE occurred. For each
episode, patients were categorized based on the total num-
ber of AEs they experienced during that episode (0, 1–2,
3–4, or > 4 AEs).
Total costs were tabulated from a payer perspective and
included costs related to hospitalization, outpatient ser-
vices, emergency department visits, chemotherapy and
other (non-chemotherapy) medications.
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Statistical analyses
Mean AE counts and healthcare costs were calculated for
each treatment cohort. Costs were adjusted to 2011 US dol-
lars using the Medical Care Component of the U.S. Con-
sumer Price Index (US Dept. of Labor and Bureau of Labor
Statistics). In order to account for variation in the length of
treatment episodes, average monthly costs were calculated
by dividing the total costs incurred during the treatment
episode by the episode length, in months. We evaluated
average total costs as well as average costs categorize by re-
source type (hospitalization, outpatient services, emergency
department visits, chemotherapy and other medications).
The incremental monthly healthcare costs associated with
the presence of AEs, compared with no AEs, were esti-
mated using generalized linear models, controlling for age
(linear) and Charlson Comorbidity Index (categorized as 0,
1, 2, and 3+) at study index date. The incremental cost as-
sociated with increasing the number of AEs was also esti-
mated using similar generalized linear models. All analyses
were performed using SAS version 9.3 (SAS Institute, Inc.,
Cary, NC) (SAS Institute, Inc 2012).
Results
We identified 15,443 women with mBC that met inclusion
criteria and were treated FL or SL with either a taxane or
capecitabine (Figure 1). Mean age was approximately 50
years in all treatment cohorts (Table 2). Taxanes were used
more frequently than capecitabine in both FL treatment
(n = 7,934 vs. 634, respectively) and SL treatment (n =
6,339 vs. 360, respectively; Table 2). The mean length of
FL treatment episodes was 161 days for regimens contain-
ing taxanes and 186 days for regimens containing capecit-
abine. Treatment duration was slightly shorter for SL,
with a mean of 98 days for taxanes and 145 days for cape-
citabine. The mean length of treatment was significantly
longer in patients who experienced at least one AE com-
pared to those with no AEs in both FL and SL regimens
(p <0.001 for each, Table 2). During FL treatment, 83.8%
Figure 1 Flowchart of sample selection.
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of taxane users and 45.1% of capecitabine users experienced
at least one AE (p <0.0001). Adverse events were slightly
less common in SL treatment, occurring in 68.0% of taxane
users and 42.2% of capecitabine users (p <0.0001). Anemia
was the most frequently diagnosed AE for all treatment co-
horts, occurring in 20.5% of FL taxane users, 12.9% of FL
capecitabine users, 16.0% of SL taxane users and 13.6% of
SL capecitabine users (Table 2). Other commonly observed
AEs included arthralgia, dyspnea, fatigue, infection and
pyrexia.
Unadjusted mean total monthly costs ranged from $6,372
to $10,939, depending on the treatment cohort (Table 2).
Costs were higher in those treated with taxanes than in
those treated with capecitabine, in both FL and SL set-
tings. This difference was significant in those receiving FL
treatment (p <0.0001) and was driven by chemotherapy
costs in this cohort.
Adjusted total monthly costs were also significantly higher
in those who experienced at least one AE than in those with-
out AEs, both in FL (incremental cost: taxanes $1,142, p <
0.0001; capecitabine $1,817, p < 0.05) and SL (incremental
cost: taxanes $1,448, p < 0.0001; capecitabine $4,437, p <
0.05) settings. In addition, total adjusted incremental costs
increased as the number of AEs increased for all treatment
cohorts (Table 3). The occurrence of AEs had the greatest
and most consistent impact on hospitalization costs, which
were significantly higher for those experiencing at least one
AE and increased with the number of AEs in all treatment
cohorts (Table 3). Chemotherapy costs were also higher for
those experiencing AEs, though this trend was not signifi-
cant for the SL capecitabine group. The impact of AEs on
other cost categories differed across treatment cohorts. For
example, among individuals treated FL or SL with capecita-
bine, costs related to other medications and ER visits were
significantly higher in patients experiencing AEs than in
those without AEs. However, for those receiving taxanes,
costs of non-chemotherapy medications were lower while
ER visit costs were not significantly different in patients ex-
periencing AEs compared to those without AEs (Table 3). In
the FL cohorts, total costs increased, despite decreases in
outpatient costs.
Discussion
Metastatic breast cancer imparts a substantial economic
burden on patients and society. We found that mean total
monthly healthcare costs for mBC patients treated with a
taxane or capecitabine ranged from $6,372 to $10,939, de-
pending on the treatment cohort. These results are similar
to those from a previously published study, which found
that the average total healthcare cost in mBC patients re-
ceiving chemotherapy was $161,816 over a mean follow-
up time of 532 days, or $9,252 per month (adjusted to
2011 US dollars) (Vera-Llonch et al. 2011). Results of the
present study also demonstrate that experiencing any
chemotherapy-related AEs increased monthly healthcare
costs by $1,142 to $4,437. This is a considerable economic
impact, even relative to the overall cost of healthcare in
these patients. Furthermore, a trend was observed in which
costs increased as the number of AEs increased. The incre-
mental cost of AEs was primarily driven by greater
hospitalization rates amongst those experiencing AEs. This
aligns with results from previous studies, which found that
cost increases associated with chemotherapy-related AEs
were related to increases in pharmacy and hospitalization
costs (Guerin et al. 2011; Hurvitz et al. 2012).
It was interesting to note that those with AEs also had
greater chemotherapy costs than those without AEs across
all treatment cohorts. This suggests that experiencing AEs
may be a marker of greater chemotherapy exposure. In
other words, those with the greatest treatment persistence
would both incur greater chemotherapy costs and be more
likely to experience AEs. This was further supported by
the finding that treatment duration was significantly lon-
ger in those experiencing AEs than in those without AEs
in both FL and SL regimens. However, this issue is not
straightforward. Because chemotherapy-related AEs can
result in treatment interruptions and dose reductions, we
Table 1 Diagnosis codes for adverse event identification
Adverse event type ICD-9 code(s)
Anemia 281, 283, 284, 285
Arthralgia 719.4x
Elevated Bilirubin 277.4
Constipation 546.0x
Diarrhea 007, 009.x, 787.91, 564.5
Dyspnea 786
Edema 782.3
Fatigue 780.7x
Infection 0001.xx-018.xx, 030.xx-041.xx, 050.xx-057.xx,
110.xx-118.xx, 070.xx-079.xx, 130.xx-136.xx,
400.xx-486.xx, 045.xx-049.xx, 995.91, 995.92
Injection site reaction 999.39
Leukopenia 288.8, 288.9
Elevated liver
enzymes (AST, ALT)
790.4
Myalgia 729.1
Nausea/vomiting 780.0x, 780.52
Neutropenia 288.0x
Peripheral neuropathy 337.0x, 337.1, 356.x, 357.x
Pharyngitis 462
Pyrexia 780.6x
Rash 693.0, 708.8, 708.9, 782.1
Stomatitis 528.0x
Thrombocytopenia 287.4, 99.05
ICD-9 International Classification of Diseases version 9.
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might conversely expect that those with AEs would re-
ceive less chemotherapy and therefore have lower chemo-
therapy costs. Our study allowed for breaks in therapy,
only terminating treatment episodes if there was a gap in
therapy of at least 45 days. However, shorter AE-related
treatment gaps could exist within a single treatment epi-
sode. Most likely, both of these factors are operating in
our study population simultaneously.
We found that capecitabine-based regimens were asso-
ciated with fewer AEs, and lower costs, than taxane-based
regimens. This was true in both FL and SL treatment co-
horts, though the difference was only significant in those
treated FL. We would expect that superior tolerability
might improve patient adherence and persistence. This is
supported by the finding that treatment-episodes in those
treated with capecitabine were longer, on average, than in
Table 2 Cohort characteristics, adverse event frequencies and costs
1st Line Taxane 1st Line Capecitabine 2nd Line Taxane 2nd Line Capecitabine
Number of patients 7934 634 6339 360
Age, mean (years) 49.3 51.8 48.4 50.1
Days per treatment episode, mean (SD)‡
With no adverse events 128 (110)** 150 (123)** 91 (71)** 118 (95)**
With any adverse event 167 (134) 231 (209) 101 (98) 183 (156)
Adverse events, n (%)
Any adverse event† 6647 (83.8) 286 (45.1)** 4313 (68.0) 152 (42.2)**
Liver enzymes increased 5 (0.1) 0 (0.0) 1 (0.0) 0 (0.0)
Anemia 1627 (20.5) 82 (12.9) 1017 (16.0) 49 (13.6)
Arthralgia 606 (7.6) 78 (12.3) 367 (5.8) 23 (6.4)
Bilirubin elevated 2 (0.0) 0 (0.0) 2 (0.0) 0 (0.0)
Constipation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 500 (5.0) 25 (3.9) 124 (1.9) 9 (2.5)
Dyspnea 733 (9.2) 62 (9.8) 394 (6.2) 27 (7.5)
Edema 331 (4.2) 21 (3.3) 199 (3.1) 3 (0.8)
Fatigue 817 (10.3) 43 (6.8) 493 (7.8) 26 (7.2)
Infection 750 (9.4) 39 (6.1) 354 (5.6) 29 (8.1)
Injection site reactions 4 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
Leukopenia 40 (0.5) 0 (0.0) 29 (0.5) 1 (0.3)
Myalgia 171 (2.2) 8 (1.3) 105 (1.6) 3 (0.8)
Nausea/vomiting 206 (2.6) 13 (2.0) 113 (1.8) 12 (3.3)
Neutropenia 203 (2.6) 2 (0.3) 12 (0.2) 0 (0.0)
Peripheral neuropathy 195 (2.5) 18 (2.8) 261 (4.1) 10 (2.8)
Pharyngitis 181 (2.3) 10 (1.6) 100 (1.6) 5 (1.4)
Pyrexia 929 (11.7) 27 (4.3) 247 (3.9) 14 (3.9)
Rash 312 (3.9) 17 (2.7) 161 (2.5) 7 (1.9)
Stomatitis 101 (1.3) 2 (0.3) 32 (0.5) 2 (0.6)
Thrombocytopenia 64 (0.8) 3 (0.5) 6 (0.1) 0 (0.0)
Unadjusted monthly costs, mean (SD)†
Chemotherapy costs $6,256 (4659) $3,761 (3221)** $3,062 (4096) $4,344 (3380)**
Other medication costs $312 (794) $279 (651) $268 (873) $281 (560)
Hospitalization costs $817 (4084) $1,065 (6159) $490 (2826) $1,655 (7324)*
Emergency department costs $90 (696) $46 (180)** $99 (691) $68 (312)*
Outpatient services costs $293 (2607) $1,220 (4465)** $7,021 (5720) $4,032 (6826)**
Total costs $7,770 (6880) $6,372 (8313)** $10,939 (8145) $10,381 (11139)
SD standard deviation, ‡p-values compare those with no AEs vs. those with AEs, †p-values compare taxane vs. capecitabine treated patients for each treatment
line, *p < 0.05, **p < 0.0001.
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those treated with a taxane, in both FL and SL settings.
However, it is interesting to note that incremental costs
associated with AEs are numerically higher in those
treated with capecitabine than in those treated with tax-
anes. It is possible that, while capecitabine treatment is as-
sociated with fewer AEs and lowers costs overall, the AEs
experienced by capecitabine-treated individuals are of a
greater severity or longer duration than in those treated
with taxanes. Yet, with the current study we are unable to
ascertain the severity or length of AEs.
Finally, our results indicate that AEs are less common
in patients treated SL than in those receiving FL treat-
ment. Perhaps the most likely explanation for this is that
FL treatment episodes were longer, on average, than SL
treatment episodes, which means that FL patients had
more time in which to experience an AE.
Limitations
Though healthcare claims databases provide rich infor-
mation for analyzing healthcare utilization and costs,
this type of data has a number of limitations. First, we
were dependent on healthcare claims for the diagnosis
and treatment information used to identify and classify
patients. Furthermore, information on certain potential
confounding variables, such as disease severity, was un-
available and, thus, could not be included in regression
models. The degree to which we could look back histor-
ically was also limited. For these reasons, patients may
have been erroneously included in or excluded from the
study or incorrectly assigned to treatment cohorts. In
addition, small sample sizes prevented us from analyz-
ing the impact of individual AEs on costs. We also re-
lied upon diagnosis codes to indicate the presence of
Table 3 Regression estimated average incremental monthly costs by adverse event count‡
1st Line Taxane 1st Line Capecitabine 2nd Line Taxane 2nd Line Capecitabine
With any adverse event, $
Chemotherapy costs $478** $630* $513** $118
Other medication costs -$5 $176* -$54* $139*
Hospitalization costs $920** $1,745* $441** $2,771*
Emergency department costs $29 $43* $17 $91*
Outpatient services costs -$280** -$777* $531* $1,319
Total costs $1,142** $1,817* $1,448** $4,437*
With 1–2 adverse events, $
Chemotherapy costs $342* $75 $22 $1
Other medication costs -$3 $151* -$13 $52
Hospitalization costs $169 $755 $57 $1,018
Emergency department costs -$6 $25 $23 $34
Outpatient services costs -$226* -$903* $154 -$19
Total costs $276 $104 $243 $1,087
With 3–4 adverse events, $
Chemotherapy costs $549* $551 $325* -$283
Other medication costs $14 $220* -$101* $260*
Hospitalization costs $296 $1,648 $183 $1,221
Emergency department costs -$12 $50 -$3 $174*
Outpatient services costs -$182 -$817 $1,103** $693
Total costs $667* $1,652 $1,506** $2,065
With greater than 4 adverse events, $
Chemotherapy costs $488* $1,537** $1,053** $535
Other medication costs -$17 $192* -$71* $191*
Hospitalization costs $1,389** $3,393** $934** $5,777**
Emergency department costs $54* $67* $24 $128*
Outpatient services costs -$353** -$555 $593* $3,323*
Total costs $1,562** $4,635** $2,533** $9,954**
‡Relative to those with no adverse events and adjusted for age (linear) and Charlson Comorbidity Index (categorized 0, 1, 2, and 3+), *p < 0.05, **p < 0.0001.
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AEs. Adverse events were only captured if they (1) re-
sulted in a service in which a specific diagnosis was
made, or (2) required a specified confirmatory labora-
tory test. Moreover, patients in this study were treated
in a community setting, which differs substantially from
clinical trials, where events of every severity are docu-
mented. Perhaps as a result, adverse event rates in this
study were generally lower than those observed in the
clinical trials for these agents (Blum et al. 1999; Jones
et al. 2005). For example, though package inserts report
frequencies of nausea and vomiting exceeding 30% for
both taxanes and capecitabine, these events were only
diagnosed in 1.8 to 3.3% of patients in this study (Taxotere
2013; Taxol 2011; Xeloda 2011). The undetected AEs were
probably of lower severity, and would, therefore, only mod-
estly impact costs. However, out of pocket payments were
also excluded, since only those costs that were paid by
employer-based insurance plans participating in Market-
scan were captured. Given the high probability that we
omitted at least some AEs and costs, the results of the
present study likely underestimate the true cost of
chemotherapy-related AEs in this population. Finally, be-
cause Medicare data were not included in this analysis, the
results are only applicable to the population of mBC pa-
tients under age 65.
Conclusions
Adverse events are common in women with mBC receiving
taxane- and capecitabine-based chemotherapy regimens.
These AEs may impact treatment dose and duration and
are also associated with substantial increases in costs for
both FL and SL treatment regimens. Clinicians and patients
should consider the impact of AEs on costs and outcomes
when selecting treatment options for women with mBC.
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